Cardiovascular disease remains as the Number 1 killer in western societies. Currently, ischemic damage to the heart cannot be repaired by conventional medical care therefore only palliative treatments exist. Stem cell transplantation is a promising strategy for therapeutic cardiac regeneration, but current therapies are limited by inefficient interaction between potentially beneficial cells (either exogenously transplanted or endogenously recruited) and the injured tissue. The development of new methods that achieve selective, targeted cell-cell interactions has the potential to revolutionize cardiovascular regenerative medicine. In this application, we pioneer the concept of magnetic bi-functional cell engager (MagBICE) for therapeutic cell targeting. Iron nanoparticles (Fe) are linked with Fab' fragments directed against the therapeutic cell (Fab1) and the injured cell (Fab2). The central hypothesis is that: MagBICE (Fab1-Fe-Fab2) delivered systemically will capture mobilized stem cells in the blood and redirect them to injured tissue via the circulatory system (see cartoon illustration). MagBICE enables molecular recognition (via Fab') and physical enrichment by external magnetic field (via Fe). Moreover, translatability of the proposed MagBICE approach to human patients should be straightforward, given that both the iron nanocore and recombinant human antibodies are in human applications. We have reduced the concept into practice in preliminary studies that form the basis for this application. We have shown: Successful conjugation of whole antibodies to FDA-approved Feraheme(r) iron nanoparticles to MagBICE; MagBICE displays desirable physicochemical features for intravenous applications; MagBICE exhibits minimal cytotoxicity and specific binding to stem cells and injured cardiomyocyte in vitro; In a proof-of-concept animal study using a rat model of acute myocardial infarction (MI), intravenously-infused MagBICE captures circulating stem cells and targets them to the injured heart, reducing scar formation and rescuing cardiac function of the animals; Antibody-mediated targeting can be synergistically coupled by magnetic attraction to further enhance cell homing and the functional benefit of MagBICE. Under the auspices of this R01 award, we seek to take advantage of the latest antibody processing technologies to create a new class of MagBICE using Fab' fragments and comprehensively study their therapeutic potencies in a rat model of acute MI. Furthermore, we plan to study the toxicity of MagBICE in animals and the synergistic benefits from magnetic focusing. Unlike conventional stem cell therapies which require exogenous cell processing and transplantation, the innovation of MagBICE is the potential to recruit a person's own endogenous stem cells and efficiently target them to the site of injury. By varying the Fab' fragments attached, and/or adding a drug payload onto the iron core, MagBICE becomes a generalizable platform technology broadly applicable to a myriad of tissue degeneration diseases involving the recruitment of endogenous stem cells to the site of injury.

Public Health Relevance

After a heart attack, the body's own stem cells are stimulated and recruited to the injured heart, but this process is not sufficient to reverse the damage. Transplantation of stem cells shows excellent safety but moderate efficacy, partially due to the poor lodging of delivered cells in the injured tissue. We plan to address both problems with a novel nanoparticle termed MagBICE, featuring: 1) capture of the body's own or delivered stem cells; 2) site-specific delivery/accumulation into the diseased region for repair; 3) incorporation of both molecular and magnetic targeting.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL123920-01A1
Application #
8888127
Study Section
Biomaterials and Biointerfaces Study Section (BMBI)
Program Officer
Danthi, Narasimhan
Project Start
2015-04-01
Project End
2020-03-31
Budget Start
2015-04-01
Budget End
2016-03-31
Support Year
1
Fiscal Year
2015
Total Cost
$374,824
Indirect Cost
$124,824
Name
North Carolina State University Raleigh
Department
Veterinary Sciences
Type
Schools of Veterinary Medicine
DUNS #
042092122
City
Raleigh
State
NC
Country
United States
Zip Code
27695
Hu, Shiqi; Ogle, Brenda M; Cheng, Ke (2018) Body builder: from synthetic cells to engineered tissues. Curr Opin Cell Biol 54:37-42
Vandergriff, Adam; Huang, Ke; Shen, Deliang et al. (2018) Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide. Theranostics 8:1869-1878
Tang, Junnan; Su, Teng; Huang, Ke et al. (2018) Targeted repair of heart injury by stem cells fused with platelet nanovesicles. Nat Biomed Eng 2:17-26
Tang, Junnan; Wang, Jinqiang; Huang, Ke et al. (2018) Cardiac cell-integrated microneedle patch for treating myocardial infarction. Sci Adv 4:eaat9365
Tang, Jun-Nan; Cores, Jhon; Huang, Ke et al. (2018) Concise Review: Is Cardiac Cell Therapy Dead? Embarrassing Trial Outcomes and New Directions for the Future. Stem Cells Transl Med 7:354-359
Hensley, Michael Taylor; Tang, Junnan; Woodruff, Kathleen et al. (2017) Intracoronary allogeneic cardiosphere-derived stem cells are safe for use in dogs with dilated cardiomyopathy. J Cell Mol Med 21:1503-1512
Tang, Junnan; Cui, Xiaolin; Caranasos, Thomas G et al. (2017) Heart Repair Using Nanogel-Encapsulated Human Cardiac Stem Cells in Mice and Pigs with Myocardial Infarction. ACS Nano 11:9738-9749
Cores, Jhon; Hensley, M Taylor; Kinlaw, Kathryn et al. (2017) Safety and Efficacy of Allogeneic Lung Spheroid Cells in a Mismatched Rat Model of Pulmonary Fibrosis. Stem Cells Transl Med 6:1905-1916
Dinh, Phuong-Uyen C; Cores, Jhon; Hensley, M Taylor et al. (2017) Derivation of therapeutic lung spheroid cells from minimally invasive transbronchial pulmonary biopsies. Respir Res 18:132
Tang, Junnan; Vandergriff, Adam; Wang, Zegen et al. (2017) A Regenerative Cardiac Patch Formed by Spray Painting of Biomaterials onto the Heart. Tissue Eng Part C Methods 23:146-155

Showing the most recent 10 out of 22 publications